Nat Med:都是肠癌也有不同 对症治疗是正道

2015-10-15 佚名 生物谷

近日,一项最新研究指出,虽然都叫结肠直肠癌(colorectal cancer),但根据生物学特性不同,结肠直肠癌可以被分为四种不同的疾病。这项研究将帮助医生根据不同的肠癌类型采取不同的治疗措施,并促进不同靶向治疗药物的开发。相关研究结果发表在国际学术期刊Nature medicine上。   这项由多个国家的科学家共同完成的研究将许多不同的结肠直肠癌研究数据汇集到一起获得了世界上

近日,一项最新研究指出,虽然都叫结肠直肠癌(colorectal cancer),但根据生物学特性不同,结肠直肠癌可以被分为四种不同的疾病。这项研究将帮助医生根据不同的肠癌类型采取不同的治疗措施,并促进不同靶向治疗药物的开发。相关研究结果发表在国际学术期刊Nature medicine上。

 
这项由多个国家的科学家共同完成的研究将许多不同的结肠直肠癌研究数据汇集到一起获得了世界上最大的结肠直肠癌数据集,并根据这些数据对肠癌亚型进行了分类。
 
该项研究整合了世界范围内3443名肠癌病人的数据,其中包括了许多如基因突变,基因活性,免疫系统激活,细胞代谢,癌细胞类型以及向周围组织侵袭能力的分子学和临床数据。他们通过结合各种参数开发了数学算法,并以此对肠癌亚型进行了分组,提高了之前基于小数据集进行的疾病类型分类的准确度。
 
研究人员发现有大约87%的肠癌归属于四个亚型中的一种,而这四种具有不同分子特征的肠癌亚型,每一种都具有自身独特特征,使得它们对于相同治疗策略具有不同的应答情况。
 
其中一种类型的肠癌通常获得诊断较晚(III期和IV期),并且这类肠癌具有高转移能力,相比于其它类型的肠癌,病人生存率也更差。而对于另外一种类型的肠癌亚型来说,即使出现复发情况,病人的生存率也会更高。
 
研究人员指出,这项研究鉴定出了四种不同类型的肠癌,每一种都具有特定的遗传和生物学特性,并且其中一些类型更具侵袭性也更加致命,这会帮助医生找出病情更加恶劣的病人,并进行相应治疗,同时这项研究也会促进新的分子诊断检测方法的开发,用以区分不同的肠癌亚型,并帮助病人选择合理有效的治疗手段。

原文出处:

Justin Guinney, Rodrigo Dienstmann,The consensus molecular subtypes of colorectal cancer.NAT med.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880840, encodeId=398a188084002, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 03:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50420, encodeId=100750420c5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 12:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011061, encodeId=976e2011061b7, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jun 03 07:06:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39429, encodeId=57b939429cf, content=这篇文章还是很有意思的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Mon Oct 19 06:57:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606661, encodeId=8606160666192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 17 00:06:00 CST 2015, time=2015-10-17, status=1, ipAttribution=)]
    2016-01-12 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880840, encodeId=398a188084002, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 03:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50420, encodeId=100750420c5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 12:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011061, encodeId=976e2011061b7, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jun 03 07:06:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39429, encodeId=57b939429cf, content=这篇文章还是很有意思的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Mon Oct 19 06:57:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606661, encodeId=8606160666192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 17 00:06:00 CST 2015, time=2015-10-17, status=1, ipAttribution=)]
    2015-12-30 xyfg98

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1880840, encodeId=398a188084002, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 03:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50420, encodeId=100750420c5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 12:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011061, encodeId=976e2011061b7, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jun 03 07:06:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39429, encodeId=57b939429cf, content=这篇文章还是很有意思的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Mon Oct 19 06:57:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606661, encodeId=8606160666192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 17 00:06:00 CST 2015, time=2015-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880840, encodeId=398a188084002, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 03:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50420, encodeId=100750420c5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 12:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011061, encodeId=976e2011061b7, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jun 03 07:06:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39429, encodeId=57b939429cf, content=这篇文章还是很有意思的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Mon Oct 19 06:57:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606661, encodeId=8606160666192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 17 00:06:00 CST 2015, time=2015-10-17, status=1, ipAttribution=)]
    2015-10-19 fengzhigu

    这篇文章还是很有意思的!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880840, encodeId=398a188084002, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 12 03:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50420, encodeId=100750420c5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 12:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011061, encodeId=976e2011061b7, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jun 03 07:06:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39429, encodeId=57b939429cf, content=这篇文章还是很有意思的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Mon Oct 19 06:57:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606661, encodeId=8606160666192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Oct 17 00:06:00 CST 2015, time=2015-10-17, status=1, ipAttribution=)]

相关资讯

招募患者:盐酸安罗替尼治疗转移性结直肠癌的IIb期临床研究

1.  试验药物简介 盐酸安罗替尼是小分子多靶点酪氨酸激酶抑制剂,本试验的目标人群是转移性结直肠癌患者。 2.  试验目的 与安慰剂联合最佳支持治疗对照,评价盐酸安罗替尼胶囊联合最佳支持治疗用于晚期结直肠癌患者的有效性和安全性。 3.  试验设计 试验分类:安全性和有效性 试验分期:II期 设计类型:平行分组(试验组:安罗替尼,对照组:安慰剂)

CSCO 2015:陈功:精准医疗时代的个体化结直肠癌辅助化疗

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会在厦门举行。在今天的会议上,来自中山大学肿瘤防治中心的陈功教授做了题为《精准医疗时代的个体化结直肠癌辅助化疗》的报告。以下是陈功教授演讲内容:结直肠癌(colorectal cancer,CRC)是我国最常见的消化道恶性肿瘤之一,而且发病率和死亡率呈上升趋势。据2015年3 月发布的《2015 年中国肿瘤登记年报》数据显示,全国恶性肿瘤发病

FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌

近日,美国食品药品监督管理局(FDA)批准了Lonsurf用于对其他治疗无应答的晚期结直肠癌患者(NEJM:TAS-102对难治性转移性结直肠癌的临床效果)(RECOURSE试验III期:TAS-102对比安慰剂治疗已给予最佳支持治疗且能耐受标准化疗的mCRC患者)。 Lonsurf是一种口服药,是三氟胸苷和 tipiracil 盐酸盐片,又称TAS-102,用于治疗已经化疗

Sci Rep:多吃鱼可降低结直肠的发病风险

Nature:多吃鱼可降低结直肠的发病风险近日,来自中山大学的一项研究表明,吃鱼可降低结直肠癌的发病率,该研究结果于8月25日在线发表于《Nature》。关于某些鱼的摄入与结直肠癌发病风险之间的关系仍存在争议。该项大型的队列研究旨在探讨中国人群某些鱼的摄入与结直肠癌发病风险之间的关系。研究纳入了2010年7月至2014年11月期间的1189 例结直肠癌患者以及1189名年龄性别与之匹配的对照者。以

Cell:模拟病毒感染带来癌症新疗法

近日,发表于国际杂志Cell上的一篇研究论文中,来自玛嘉烈公主癌症中心(Princess Margaret Cancer Centre)等处的研究人员通过对结直肠癌干细胞进行靶向研究阐明了一种模拟病毒的新机制,这或可潜在诱发免疫反应来抵御类似于感染引发的癌症。研究者De Carvalho说道,通过模拟病毒感染或许就可以诱骗机体免疫系统“看见”癌细胞,并且将癌细胞视作感染,进而就可以帮助清除癌细胞,